Andrew Amiel
Corporate Officer/Principal presso REMEGENIX, INC.
Profilo
Andrew Amiel is the founder of Lamiel Partners.
He currently works as the Vice President of Business Development at RemeGenix, Inc. Previously, he worked as an Associate at Landmark Ventures, Inc. Mr. Amiel completed his undergraduate degree at New York University.
Posizioni attive di Andrew Amiel
| Società | Posizione | Inizio |
|---|---|---|
| REMEGENIX, INC. | Corporate Officer/Principal | - |
Precedenti posizioni note di Andrew Amiel
| Società | Posizione | Fine |
|---|---|---|
Landmark Ventures, Inc.
 Landmark Ventures, Inc. Investment ManagersFinance Landmark Ventures, Inc. provides venture capital management services. The firm offers strategic advice and investment banking services to companies in the information technology and materials technology sectors. It also provides private placements, capital raising, due diligence, and valuation advisory services. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
| Lamiel Partners | Fondatore | - |
Formazione di Andrew Amiel
| New York University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Landmark Ventures, Inc.
Landmark Ventures, Inc. Investment ManagersFinance Landmark Ventures, Inc. provides venture capital management services. The firm offers strategic advice and investment banking services to companies in the information technology and materials technology sectors. It also provides private placements, capital raising, due diligence, and valuation advisory services. The company is headquartered in New York, NY. | Finance |
RemeGenix, Inc.
 RemeGenix, Inc. Pharmaceuticals: MajorHealth Technology RemeGenix, Inc. is a biotechnology company, which engages in the development of drug MoBA which is used for treatment of Alzheimer's disease. Its product pipe lines include NoMAD, which is one of the preferred animal models used in the development of a variety of Alzheimer's and ementia drug development efforts and MoBA. The company was founded by Luciano D'Adamio and J. Kelly Ganjei on April 28, 2006 and is headquartered in Bethesda, MD. | Health Technology |
| Lamiel Partners |
- Borsa valori
- Insiders
- Andrew Amiel
